An evaluation of the role of properdin in alternative pathway activation on Neisseria meningitidis and Neisseria gonorrhoeae

Journal of Immunology

Volumn 185, Issue 1, 2010, Pages 507-516

  Agarwal, Sarika ^a   Ferreira, Viviana P ^b,c   Cortes, Claudio ^b,c   Pangburn, Michael K ^c   Rice, Peter A ^a   Ram, Sanjay ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b MEDICAL COLLEGE OF OHIO   (United States)

^c UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C3; MONOCLONAL ANTIBODY; OLIGOMER; PROPERDIN; ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE;

ARTICLE; BACTERIAL STRAIN; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT DEPOSITION; CONTROLLED STUDY; NEISSERIA GONORRHOEAE; NEISSERIA MENINGITIDIS; NEISSERIACEAE INFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; BACTERIUM ADHERENCE; COMPARATIVE STUDY; ENZYME STABILITY; GENETICS; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; PHYSIOLOGY; PROTEIN BINDING;

BACTERIAL ADHESION; COMPLEMENT C3; COMPLEMENT C3 CONVERTASE, ALTERNATIVE PATHWAY; COMPLEMENT PATHWAY, ALTERNATIVE; ENZYME STABILITY; HUMANS; NEISSERIA GONORRHOEAE; NEISSERIA MENINGITIDIS, SEROGROUP A; NEISSERIA MENINGITIDIS, SEROGROUP B; NEISSERIA MENINGITIDIS, SEROGROUP C; NEISSERIA MENINGITIDIS, SEROGROUP W-135; NEISSERIA MENINGITIDIS, SEROGROUP Y; PROPERDIN; PROTEIN BINDING;

EID: 77956221152     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0903598     Document Type: Article

References (56)

1. Nolan, K. F., S. Kaluz, J. M. Higgins, D. Goundis, and K. B. Reid. 1992. Characterization of the human properdin gene. Biochem. J. 287: 291-297.
2. Pangburn, M. K. 1989. Analysis of the natural polymeric forms of human properdin and their functions in complement activation. J. Immunol. 142: 202-207.
3. Smith, C. A., M. K. Pangburn, C. W. Vogel, and H. J. Müller- Eberhard. 1984. Molecular architecture of human properdin, a positive regulator of the alternative pathway of complement. J. Biol. Chem. 259: 4582-4588.
4. Fearon, D. T., and K. F. Austen. 1975. Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase. J. Exp. Med. 142: 856-863.
5. Pillemer, L., L. Blum, I. H. Lepow, O. A. Ross, E. W. Todd, and A. C. Wardlaw. 1954. The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena. Science 120: 279-285.
6. Spitzer, D., L. M. Mitchell, J. P. Atkinson, and D. E. Hourcade. 2007. Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly. J. Immunol. 179: 2600-2608.
7. Hourcade, D. E. 2006. The role of properdin in the assembly of the alternative pathway C3 convertases of complement. J. Biol. Chem. 281: 2128-2132.
8. Densen, P., J. M. Weiler, J. M. Griffiss, and L. G. Hoffmann. 1987. Familial properdin deficiency and fatal meningococcemia. Correction of the bactericidal defect by vaccination. N. Engl. J. Med. 316: 922-926.
9. Fijen, C. A., E. J. Kuijper, A. J. Hannema, A. G. Sjöholm, and J. P. van Putten. 1989. Complement deficiencies in patients over ten years old with meningococcal disease due to uncommon serogroups. [see comments] Lancet 2: 585-588.
10. Nielsen, H. E., C. Koch, P. Magnussen, and I. Lind. 1989. Complement deficiencies in selected groups of patients with meningococcal disease. Scand. J. Infect. Dis. 21: 389-396.
11. Ross, S. C., and P. Densen. 1984. Complement deficiency states and infection: epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency. Medicine (Baltimore) 63: 243-273.
12. Sjöholm, A. G., J. H. Braconier, and C. Söderström. 1982. Properdin deficiency in a family with fulminant meningococcal infections. Clin. Exp. Immunol. 50: 291-297.
13. Braconier, J. H., A. G. Sjöholm, and C. Söderström. 1983. Fulminant meningococcal infections in a family with inherited deficiency of properdin. Scand. J. Infect. Dis. 15: 339-345.
14. Nielsen, H. E., and C. Koch. 1987. Congenital properdin deficiency and meningococcal infection. Clin. Immunol. Immunopathol. 44: 134-139.
15. Genel, F., F. Atlihan, N. Gulez, A. G. Sjöholm, L. Skattum, and L. Truedsson. 2006. Properdin deficiency in a boy with fulminant meningococcal septic shock. Acta Paediatr. 95: 1498-1500. (Pubitemid 44643569)
16. Cunliffe, N. A., N. Snowden, E. M. Dunbar, and M. R. Haeney. 1995. Recurrent meningococcal septicaemia and properdin deficiency. J. Infect. 31: 67-68.
17. Späth, P. J., A. G. Sjöholm, G. N. Fredrikson, G. Misiano, R. Scherz, U. B. Schaad, B. Uhring-Lambert, G. Hauptmann, J. Westberg, M. Uhlén, et al. 1999. Properdin deficiency in a large Swiss family: identification of a stop codon in the properdin gene, and association of meningococcal disease with lack of the IgG2 allotype marker G2m(n). Clin. Exp. Immunol. 118: 278-284.
18. Schlesinger, M., U. Mashal, J. Levy, and Z. Fishelson. 1993. Hereditary properdin deficiency in three families of Tunisian Jews. Acta Paediatr. 82: 744-747. (Pubitemid 23233708)
19. Schlesinger, M., Z. Nave, Y. Levy, P. E. Slater, and Z. Fishelson. 1990. Prevalence of hereditary properdin, C7 and C8 deficiencies in patients with meningococcal infections. Clin. Exp. Immunol. 81: 423-427.
20. Figueroa, J. E., and P. Densen. 1991. Infectious diseases associated with complement deficiencies. Clin. Microbiol. Rev. 4: 359-395.
21. Harboe, M., and T. E. Mollnes. 2008. The alternative complement pathway revisited. J. Cell. Mol. Med. 12: 1074-1084.
22. Hourcade, D. E. 2008. Properdin and complement activation: a fresh perspective. Curr. Drug Targets 9: 158-164.
23. Jarva, H., S. Ram, U. Vogel, A. M. Blom, and S. Meri. 2005. Binding of the complement inhibitor C4bp to serogroup B Neisseria meningitidis. J. Immunol. 174: 6299-6307.
24. Jarvis, G. A., and N. A. Vedros. 1987. Sialic acid of group B Neisseria meningitidis regulates alternative complement pathway activation. Infect. Immun. 55: 174-180.
25. Madico, G., J. Ngampasutadol, S. Gulati, U. Vogel, P. A. Rice, and S. Ram. 2007. Factor H binding and function in sialylated pathogenic neisseriae is influenced by gonococcal, but not meningococcal, porin. J. Immunol. 178: 4489-4497.
26. Madico, G., J. A. Welsch, L. A. Lewis, A. McNaughton, D. H. Perlman, C. E. Costello, J. Ngampasutadol, U. Vogel, D. M. Granoff, and S. Ram. 2006. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J. Immunol. 177: 501-510.
27. Parsons, N. J., P. V. Patel, E. L. Tan, J. R. C. Andrade, C. A. Nairn, M. Goldner, J. A. Cole, and H. Smith. 1988. Cytidine 5′-monophospho-N-acetyl neuraminic acid and a low molecular weight factor from human blood cells induce lipopolysaccharide alteration in gonococci when conferring resistance to killing by human serum. Microb. Pathog. 5: 303-309.
28. Ram, S., M. Cullinane, A. M. Blom, S. Gulati, D. P. McQuillen, B. G. Monks, C. O'Connell, R. Boden, C. Elkins, M. K. Pangburn, et al. 2001. Binding of C4b-binding protein to porin: a molecular mechanism of serum resistance of Neisseria gonorrhoeae. J. Exp. Med. 193: 281-295.
29. Ram, S., D. P. McQuillen, S. Gulati, C. Elkins, M. K. Pangburn, and P. A. Rice. 1998. Binding of complement factor H to loop 5 of porin protein 1A: a molecular mechanism of serum resistance of nonsialylated Neisseria gonorrhoeae. J. Exp. Med. 188: 671-680.
30. Ram, S., A. K. Sharma, S. D. Simpson, S. Gulati, D. P. McQuillen, M. K. Pangburn, and P. A. Rice. 1998. A novel sialic acid binding site on factor H mediates serum resistance of sialylated Neisseria gonorrhoeae. J. Exp. Med. 187: 743-752.
31. Schneider, M. C., R. M. Exley, H. Chan, I. Feavers, Y. H. Kang, R. B. Sim, and C. M. Tang. 2006. Functional significance of factor H binding to Neisseria meningitidis. J. Immunol. 176: 7566-7575.
32. Schneider, M. C., R. M. Exley, S. Ram, R. B. Sim, and C. M. Tang. 2007. Interactions between Neisseria meningitidis and the complement system. Trends Microbiol. 15: 233-240.
33. Schneider, M. C., B. E. Prosser, J. J. Caesar, E. Kugelberg, S. Li, Q. Zhang, S. Quoraishi, J. E. Lovett, J. E. Deane, R. B. Sim, et al. 2009. Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature 458: 890-893.
34. Vogel, U., and M. Frosch. 1999. Mechanisms of neisserial serum resistance. Mol. Microbiol. 32: 1133-1139.
35. Farries, T. C., J. T. Finch, P. J. Lachmann, and R. A. Harrison. 1987. Resolution and analysis of 'native' and 'activated' properdin. Biochem. J. 243: 507-517.
36. Findlow, H., U. Vogel, J. E. Mueller, A. Curry, B. M. Njanpop-Lafourcade, H. Claus, S. J. Gray, S. Yaro, Y. Traoré, L. Sangaré, et al. 2007. Three cases of invasive meningococcal disease caused by a capsule null locus strain circulating among healthy carriers in Burkina Faso. J. Infect. Dis. 195: 1071-1077.
37. Hoang, L. M., E. Thomas, S. Tyler, A. J. Pollard, G. Stephens, L. Gustafson, A. McNabb, I. Pocock, R. Tsang, and R. Tan. 2005. Rapid and fatal meningococcal disease due to a strain of Neisseria meningitidis containing the capsule null locus. Clin. Infect. Dis. 40: e38-e42.
38. Stephens, D. S. 2009. Biology and pathogenesis of the evolutionarily successful, obligate human bacterium Neisseria meningitidis. Vaccine 27(Suppl 2): B71-B77.
39. Claus, H., M. C. Maiden, R. Maag, M. Frosch, and U. Vogel. 2002. Many carried meningococci lack the genes required for capsule synthesis and transport. Microbiology 148: 1813-1819. (Pubitemid 34679035)
40. Deghmane, A. E., D. Giorgini, M. Larribe, J. M. Alonso, and M. K. Taha. 2002. Down-regulation of pili and capsule of Neisseria meningitidis upon contact with epithelial cells is mediated by CrgA regulatory protein. Mol. Microbiol. 43: 1555-1564.
41. Hammerschmidt, S., A. Müller, H. Sillmann, M. Mühlenhoff, R. Borrow, A. Fox, J. van Putten, W. D. Zollinger, R. Gerardy-Schahn, and M. Frosch. 1996. Capsule phase variation in Neisseria meningitidis serogroup B by slipped-strand mispairing in the polysialyltransferase gene (siaD): correlation with bacterial invasion and the outbreak of meningococcal disease. Mol. Microbiol. 20: 1211-1220.
42. Vogel, U., H. Claus, G. Heinze, and M. Frosch. 1999. Role of lipopolysaccharide sialylation in serum resistance of serogroup B and C meningococcal disease isolates. Infect. Immun. 67: 954-957.
43. Ram, S., J. Ngampasutadol, A. D. Cox, A. M. Blom, L. A. Lewis, F. St Michael, J. Stupak, S. Gulati, and P. A. Rice. 2007. Heptose I glycan substitutions on Neisseria gonorrhoeae lipooligosaccharide influence C4b-binding protein binding and serum resistance. Infect. Immun. 75: 4071-4081.
44. O'Rear, L. D., and G. D. Ross. 2001. Isolation and purification of C3 from human plasma. Curr Protoc Immunol Chapter 13:Unit 13 13.3.
45. Ferreira, V. P., C. Cortes, and M. K. Pangburn. 2010. Native polymeric forms of properdin selectively bind to targets and promote activation of the alternative pathway of complement. Immunobiology DOI:10.1016/j.imbio.2010.02. 002.
46. Schreiber, R. D., D. C. Morrison, E. R. Podack, and H. J. Müller-Eberhard. 1979. Bactericidal activity of the alternative complement pathway generated from 11 isolated plasma proteins. J. Exp. Med. 149: 870-882.
47. Heinrichs, D. E., J. A. Yethon, P. A. Amor, and C. Whitfield. 1998. The assembly system for the outer core portion of R1- and R4-type lipopolysaccharides of Escherichia coli. The R1 core-specific beta-glucosyltransferase provides a novel attachment site for O-polysaccharides. J. Biol. Chem. 273: 29497-29505.
48. Yamasaki, R., D. E. Kerwood, H. Schneider, K. P. Quinn, J. M. Griffiss, and R. E. Mandrell. 1994. The structure of lipooligosaccharide produced by Neisseria gonorrhoeae, strain 15253, isolated from a patient with disseminated infection. Evidence for a new glycosylation pathway of the gonococcal lipooligosaccharide. J. Biol. Chem. 269: 30345-30351.
49. Goldschneider, I., E. C. Gotschlich, and M. S. Artenstein. 1969. Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med. 129: 1307-1326.
50. Goldschneider, I., E. C. Gotschlich, and M. S. Artenstein. 1969. Human immunity to the meningococcus. II. Development of natural immunity. J. Exp. Med. 129: 1327-1348.
51. Figueroa, J., J. Andreoni, and P. Densen. 1993. Complement deficiency states and meningococcal disease. Immunol. Res. 12: 295-311.
52. Mitchell, L., and D. Hourcade. 2008. Inhibition of properdin-directed complement activation by serum amyloid P component. Mol. Immunol. 45: 4103. DOI: 10.1016/j.molimm.2008.08.026.
53. Schneider, H., J. M. Griffiss, G. D. Williams, and G. B. Pier. 1982. Immunological basis of serum resistance of Neisseria gonorrhoeae. J. Gen. Microbiol. 128: 13-22.
54. Densen, P., S. Gulati, and P. A. Rice. 1987. Specificity of antibodies against Neisseria gonorrhoeae that stimulate neutrophil chemotaxis. Role of antibodies directed against lipooligosaccharides. J. Clin. Invest. 80: 78-87.
55. Gulati, S., A. Cox, L. A. Lewis, F. S. Michael, J. Li, R. Boden, S. Ram, and P. A. Rice. 2005. Enhanced factor H binding to sialylated Gonococci is restricted to the sialylated lacto-N-neotetraose lipooligosaccharide species: implications for serum resistance and evidence for a bifunctional lipooligosaccharide sialyltransferase in Gonococci. Infect. Immun. 73: 7390-7397.
56. Rice, P. A., and D. L. Kasper. 1982. Characterization of serum resistance of Neisseria gonorrhoeae that disseminate. Roles of blocking antibody and gonococcal outer membrane proteins. J. Clin. Invest. 70: 157-167.